The beneficial effects of chronic and early pharmacological treatment with ethosuximide on epileptogenesis were studied in a genetic absence epilepsy model comorbid for depression. It was also investigated whether there is a critical treatment period and treatment length. Cortical excitability in the form of electrical evoked potentials, but also to cortico-thalamo-cortical network activity (spike-wave discharges, SWD and afterdischarges), white matter changes representing extra cortico-thalamic functions and depressive-like behavior were investigated. WAG/Rij rats received either ethosuximide for 2 months (post natal months 2-3 or 4-5), or ethosuximide for 4 months (2-5) in their drinking water, while control rats drank plain water. EEG measurements were made during treatment, and 6 days and 2 months post treatment. Behavioral test were also done 6 days post treatment. DTI was performed ex vivo post treatment. SWD were suppressed during treatment, and 6 days and 2 months post treatment in the 4 month treated group, as well as the duration of AD elicited by cortical electrical stimulation 6 days post treatment. Increased fractional anisotropy in corpus callosum and internal capsula on DTI was found, an increased P8 evoked potential amplitude and a decreased immobility in the forced swim test. Shorter treatments with ETX had no large effects on any parameter. Chronic ETX has widespread effects not only within but also outside the circuitry in which SWD are initiated and generated, including preventing epileptogenesis and reducing depressive-like symptoms. The treatment of patients before symptom onset might prevent many of the adverse consequences of chronic epilepsy. © 2013 Elsevier Inc. All rights reserved.
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Introduction
The gradual and slow transformation from a presymptomatic to a symptomatic phenotype in genetic epileptic rat models of absence epilepsy is a form of epileptogenesis (Giblin and Blumenfeld, 2010) . Current treatments of absence epilepsy are aimed at seizure control, not to the treatment of epilepsy, or to processes that interfere with epileptogenesis.
A recent study however, demonstrated the feasibility of antiepileptogenesis in a genetic absence model, rats of the WAG/Rij strain, a well characterized and validated genetic model of absence epilepsy (Coenen and van Luijtelaar, 2003; Depaulis and van Luijtelaar, 2006; van Luijtelaar and Coenen, 1986) . At 2 months of age, untreated WAG/ Rij rats are virtually devoid of SWD. From then on, the SWD start to appear, first in a primitive form, later more mature. At the age of 3 months 50% of WAG/Rij rats have SWD, and by 6 months of age SWD are abundantly present in the electrocorticogram (EEG) of all WAG/Rij rats (Akman et al., 2010; Coenen and van Luijtelaar, 1987; Kole et al., 2007; Schridde and van Luijtelaar, 2004) . Antiepileptogenesis was demonstrated in a study in which early and chronic (4 months) treatment with ethosuximide (ETX) in the drinking water reduced the commonly reported age-dependent increase in SWD even after medication was stopped (Blumenfeld et al., 2008) . Similar findings were reported by two other Neurobiology of Disease 60 (2013) 126-138 
